Xencor lands $13M upfront payment from MorphoSys pact; Provenge in short supply;

@FierceBiotech: Analysts fret over Pfizer's litany of pipeline snafus. Article | Follow @FierceBiotech

@JohnCFierce: Now the 3 obesity drug developers, Vivus, Orexigen and Arena, have panels lined up, when do partners step up with the big bucks? Why so late? | @JohnCFierce

> Germany's MorphoSys has inked a licensing deal with Xencor for a Phase I antibody. Xencor gets $13 million upfront along with a slate of potential milestones. "Our first in-licensing deal of a clinical compound is a further step in the execution of our plan to build a strong portfolio of proprietary therapeutic antibodies to complement those being developed by our partners," said MorphoSys CEO Dr. Simon Moroney. "The strong cash-flow from our partnered discovery business gives us the means of supporting an attractive proprietary development program, to which XmAb5574/MOR208 is an important addition." MorphoSys release

> Novartis may be pushed to raise its bid for Alcon after a legal adviser told an independent directors committee at Alcon that their support for the deal was needed. Story

> An analyst's prediction that Amylin will eventually be acquired by Eli Lilly helped buoy its shares this morning. Story

> Teva Pharmaceutical is acquiring ownership in a wound care product developer-Polyheal-with an eye to creating a new company. Report

> Rexahn is raising $10 million in a direct offering. Rexahn release

And Finally... In the short time since the FDA approved Provenge a long lineup of prostate cancer patients has already queued for the drug, creating one of the biggest backlog of orders for a new drug that's been seen for more than a decade. Report

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.